Vapotherm to Report First Quarter 2019 Financial Results

EXETER, N. H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to treat patients
of all ages suffering from respiratory distress, announced today that it
will release financial results for the first quarter of 2019 after the
close of trading on Tuesday, May 7, 2019. Vapotherm’s management team
will host a corresponding conference call beginning at 4:30 p.m. ET to
discuss the financial results and recent business developments.

To listen to the conference call on your telephone, please dial (877)
201-0168 for U.S. callers, or (647) 788-4901 for international callers,
approximately ten minutes prior to start time and reference conference
code 5167987. To listen to a live webcast, please visit the Investors
section of the Vapotherm’s website at:
The webcast replay will be available on the Vapotherm website for 90
days following the completion of the call. A replay of this conference
call will be available over the phone through May 14, 2019 by dialing
(800) 585-8367 in the U.S. or (416) 621-4642 outside of the U.S. The
replay access code is 5167987.

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer
and manufacturer of advanced respiratory technology based in Exeter, New
Hampshire, USA. The company develops innovative, comfortable,
non-invasive technologies for respiratory support of patients with
chronic or acute breathing disorders. Over 1.7 million patients have
been treated with Vapotherm Hi-VNI Technology. For more information,

Hi-VNI® Technology is mask-free noninvasive ventilation for
spontaneously breathing patients and a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It
allows for the fast, safe treatment of undifferentiated respiratory
distress with one user-friendly tool. Hi-VNI Technology’s mask-free
interface delivers optimally conditioned breathing gases, making it
comfortable for patients and reducing the risks and care complexities
associated with mask therapies. While being treated, patients can talk,
eat, drink and take oral medication.

Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of its
Vapotherm intends to use this website as a means of disclosing material,
non-public information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should monitor
the Investor Relations section of Vapotherm’s website, in addition to
following Vapotherm’s press releases, Securities and Exchange Commission
filings, public conference calls, presentations and webcasts. The
information contained on, or that may be accessed through, Vapotherm’s
website is not incorporated by reference into, and is not a part of,
this document.


Investor Relations Contact:
Mark Klausner or Mike Vallie
an ICR Company